Drug delivery tech could transform treatment of COVID-19

10 March 2021

2020_pills_tablets_bottles_biotech_manufacturing_production_big

Drug delivery innovator TFF Pharmaceuticals (Nasdaq: TFFP), a biotech company based in Texas, USA, has entered into two new collaborations exploring the use of its technology.

The firm is focused on developing and commercializing innovative drug products based on its Thin Film Freezing (TFF) tech, which it believes could improve solubility and absorption of certain drugs.

The firm has two lead drug candidates, voriconazole and tacrolimus, and plans to add to these inhalable treatments through collaborations with large drugmakers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK